Pharsight

1. Sunosi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597	AXSOME MALTA	Formulations of (R)-2-amino-3-phenylpropyl carbamate	Sep, 2037 (13 years from now)
US11648232	AXSOME MALTA	Methods and compositions for treating excessive sleepiness	Jun, 2038 (14 years from now)
US11560354	AXSOME MALTA	Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof	Mar, 2039 (15 years from now)
US11160779	AXSOME MALTA	Methods of providing solriamfetol therapy to subjects with impaired renal function	Mar, 2040 (16 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 17, 2024
Orphan Drug Exclusivity (ODE)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness with a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime ...

Dosage: TABLET;ORAL